Home Cart Sign in  
Chemical Structure| 77-67-8 Chemical Structure| 77-67-8

Structure of Ethosuximide
CAS No.: 77-67-8

Chemical Structure| 77-67-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ethosuximide is used to treat absence seizures.

Synonyms: CI-366; Zarontin; Emeside, Ethosuccimid, Ethosuximide, Ethylmethylsuccimide, Ethymal, Zarontin.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ethosuximide

CAS No. :77-67-8
Formula : C7H11NO2
M.W : 141.17
SMILES Code : O=C(C(C)(CC)C1)NC1=O
Synonyms :
CI-366; Zarontin; Emeside, Ethosuccimid, Ethosuximide, Ethylmethylsuccimide, Ethymal, Zarontin.
MDL No. :MFCD00072123

Safety of Ethosuximide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P264-P270-P301+P312+P330-P501

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02205931 Epilepsy Phase 4 Recruiting June 2019 United Kingdom ... More >> Birmingham Children's Hospital Recruiting Birmingham, United Kingdom, B4 6NH Contact: Shakti Agrawal, MBBS    0044 1213338149    shakti.agrawal@bch.nhs.uk    Principal Investigator: Shakti Agrawal, MBBS          Bristol Royal Hospital for Children Recruiting Bristol, United Kingdom, BS2 8AE Contact: Andrew Mallick, FRCPCH          Principal Investigator: Andrew Mallick          Addenbrooke's Hospital Recruiting Cambridge, United Kingdom, CB2 0QQ Contact: Alasdair Parker, MA    0044 1223 245151    alasdair.parker@addenbrookes.nhs.uk    Principal Investigator: Alasdair Parker, MA          Lancashire Teaching Hospitals NHS Foundation Trust Recruiting Lancashire, United Kingdom Contact: Helen Basu       Helen.Basu@lthtr.nhs.uk    Principal Investigator: Helen Basu          Leeds Teaching Hospital Recruiting Leeds, United Kingdom, LS1 3EX Contact: Helen McCullagh, RCPCH    0044 113 243 2799    h.mccullagh@nhs.net    Principal Investigator: Helen McCullagh, RCPCH          Alder Hey Children's Hospital Recruiting Liverpool, United Kingdom, L12 2AP Contact: Rachel Kneen, BMBS    0044 151 2525163    rachel.kneen@liverpool.ac.uk    Principal Investigator: Rachel Kneen, BMBS          Great Ormond Street Hospital Recruiting London, United Kingdom, WC1N 3JH Contact: Christin Eltze, MD Res    0044 207 405 9200 ext 5438    christin.eltze@gosh.nhs.uk    Principal Investigator: Christin Eltze, MD Res          St George's University Hospitals NHS Foundation Trust Recruiting London, United Kingdom Contact: Penny Fallon       Penny.Fallon@stgeorges.nhs.uk    Principal Investigator: Penny Fallon          Royal Manchester Children's Hospital Recruiting Manchester, United Kingdom, M13 0JE Contact: Tim Martland, RCPCH    0044 161 276 1234    timothy.martland@cmft.nhs.uk    Principal Investigator: Tim Martland, RCPCH          The Newcastle Upon Tyne Hospitals NHS Foundation Trust Recruiting Newcastle upon Tyne, United Kingdom Contact: Anita Devlin       Anita.Devlin@nuth.nhs.uk    Principal Investigator: Anita Devlin          Sheffield Children's NHS Foundation Trust Recruiting Sheffield, United Kingdom Contact: Archana Desurkar       Archana.Desurkar@sch.nhs.uk    Principal Investigator: Archana Desurkar Less <<
NCT01390909 - Completed - -
NCT01390909 - Completed - -
NCT01122381 - Terminated(poor recruitment) - -
NCT01122381 Headache, Migraine Phase 1 Phase 2 Terminated(poor recruitment) - United States, Pennsylvania ... More >> VA Pittsburgh Health Care System Pittsburgh, Pennsylvania, United States, 15240 Less <<
NCT00689585 Complex Regional Pain Syndrome... More >>s Less << Phase 2 Terminated(Recruitment difficu... More >>lt and enrolment low decision was made to stop the study.) Less << - Canada, Quebec ... More >> McGill University Health Centre Montreal, Quebec, Canada, H3G 1A4 Less <<
NCT00552526 Epilepsy Ment... More >>al Retardation Less << Phase 4 Unknown December 2013 Norway ... More >> SSE, Nevrological dep. , Rikshospitalet University hospital Oslo, Norway Less <<
NCT02973542 Irritable Bowel Syndrome Phase 2 Recruiting December 2019 France ... More >> CHU Clermont-Ferrand Recruiting Clermont-Ferrand, France, 63003 Contact: Patrick LACARIN    04 73 75 11 95    placarin@chu-clermontferrand.fr    Principal Investigator: Michel DAPOIGNY Less <<
NCT01278004 Cancer Periph... More >>eral Neuropathy Less << Phase 2 Completed - United Kingdom ... More >> Royal Marsden NHS Foundation Trust Sutton, Surrey, United Kingdom, SM2 5PT The Royal Marsden NHS Foundation Trust London, United Kingdom, SW3 6JJ Less <<
NCT00088452 Childhood Absence Epilepsy ... More >> Petit Mal Epilepsy Epilepsy Seizures Less << Phase 3 Completed - -
NCT02100046 Neuropathic Traumatic Pain ... More >> Pain NRS ≥ 4 Peripheral Neuropathic Pain Neuropathic Pain Diagnostic Questionnaire (DN4) ≥ 4 Less << Phase 2 Completed - France ... More >> CHU de Clermont-Ferrand Clermont-Ferrand, France, 63003 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

7.08mL

1.42mL

0.71mL

35.42mL

7.08mL

3.54mL

70.84mL

14.17mL

7.08mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories